User:Courtlee214/sandbox

This is a practice post to link text to other Wikipedia articles. For example, Wikipedia encourages editors to be bold.

For my course Drugs of Abuse, I have chosen to add to the Wikipedia article Empathogen–entactogen. During this next week, I will review the talk page for this article to understand what previous editors have contributed and what they are asking to be added to the article. I will focus on those requests first. I will also search for more reliable sources to add to the article. Lastly, if I can find enough reliable sources, I may add a culture or history section to discuss any significance related to the feeling of "oneness" produced by this class of psychoactive drug.

I have been working to solidify some sources for my article. An article by Michael J. Winkelman Discusses the possible therapeutic effects of empathogens, specifically MDMA. The Encyclopedia of Emotion also lists ways in which empathogens may be used for thereputic interests such as treating PTSD. A C Parrott conducted a review of the psychotherapeutic potential of MDMA. To add to the "Etymology" section, I have found a definition from the Oxford Dictionary of Psychology that discusses the differences between labling the drugs as an "entactogen" as opposed to an "empathogen." This next source will solve the lack of a sources for the opening paragraph; there is a passage from the Encyclopedia of Psychopharmacology on enactogens. The definition of MDMA in the Encylopedia of psychopharmacology talks about how the effects of MDMA may be mistaken for an amphetamine instead of an empathogen.

Lastly, I am trying to assess the cultural significance of empathogens. I am struggling to find good sources on this. Knowing that MDMA is a synthetic drug and was created in the early 1900s, I don't think that I will find good sources on the history of empathogens. I have found a source by Dale Pendell that may give incite to this issue.

Edits to be made

I will be editing this portion of the article:

Etymology

The term empathogen, meaning "generating a state of empathy", was coined in 1983–84 independently by Ralph Metzner and David E. Nichols as a term to denote a therapeutic class of drugs that includes MDMA and phenethylamine relatives. Nichols later rejected this initial terminology and adopted, instead, the term entactogen, meaning "touching within", to denote this class of drugs, asserting a concern with the potential for improper association of the term empathogen with negative connotations related to the Greek root πάθος páthos ("suffering"). Additionally, Nicholas wanted to avoid any association with the term pathogenesis. Nichols also thought the original term was limiting, and did not cover other therapeutic uses for the drugs that go beyond instilling feelings of empathy. The hybrid word entactogen is derived from the roots en ([within] Error: {{Langx}}: text has italic markup (help)), tactus (Latin: touch) and -gen ([produce] Error: {{Langx}}: text has italic markup (help)). Neither term is dominant in usage, and, despite their difference in connotation, they are essentially interchangeable, as they refer to precisely the same chemicals.

Psychological effects

Both terms adopted and used in naming the class of therapeutic drugs for MDMA and related compounds were chosen with the intention of providing some reflection of the reported psychological effects associated with drugs in the classification and distinguishing these compounds from classical psychedelic drugs such as LSD, mescaline, and psilocybin and major stimulants, such as methamphetamine and amphetamine. Chemically, MDMA is classified as a substituted amphetamine (which includes stimulants like dextroamphetamine and psychedelics like 2,5-dimethoxy-4-methylamphetamine), which makes MDMA a substituted phenethylamine (which includes other stimulants like methylphenidate and other psychedelics like mescaline) by the definition of amphetamine. While chemically related both to psychedelics and stimulants, the psychological effects experienced with MDMA were reported to provide obvious and striking aspects of personal relatedness, feelings of connectedness, communion with others, and ability to feel what others feel—in short an empathic resonance is consistently evoked." While psychedelics like LSD may sometimes yield effects of empathic resonance, these effects tend to be momentary and likely passed over on the way to some other dimension or interest. In contrast, the main characteristic that distinguishes MDMA from LSD-type experiences is the consistency of the effects of emotional communion, relatedness, emotional openness—in short, empathy and sympathy.

Examples

The chemicals below have a varying degree of entactogenic effects. Some of the chemicals have a minimal entactogenic effect while others may have a strong entactogenic effect. These substances possess other effects including serenic effects, stimulant effects, antidepressant effects, anxiolytic effects, and psychedelic effects.

I will Add this section: Therapeutic uses

Psychiatrists began using empathogens as psychotherapy tools in the 1970s despite the lack of clinical trials. In recent years, the scientific community has been revisiting the possible therapeutic uses of empathogens. Therapeutic models using MDMA have been studied because of its empathogenic properties. This type of therapy would be applicable for treating a patient who was experiencing psychological trauma such as PTSD. Traumatic memories can be linked to fear in the patients which makes engaging with these memories difficult. Administration of an empathogen such as MDMA allows the patient to disconnect from the fear associated with the traumatic memories and engage in therapy. MDMA acts by targeting the body's stress response in order to cause this therapeutic effect. In addition to reducing anxiety and a conditioned fear response, MDMA also reduces the avoidence of feelings. Patients are then able trust themselves and their therapist and engage with traumatic memories under the influence of MDMA.

Although the therapeutic effects of empathogens may be promising, drugs such as MDMA have the potential for negative effects that are counter productive in a therapy setting. For example, MDMA may make negative cognition worse. This means that a positive experience is not a guarantee and can be contingent on aspects like the setting and the patient's expectations. Additionally there is no clear model of the psychopharmalogical means for a positive or negative experience. There is also a potential concern for the neurotoxic effects of MDMA on the fiber density of serotonin neurons in the neocortex. High doses of MDMA may cause potential depletion of serotonergic axons. The same effects may not be caused by lower doses of MDMA required for treatment, however.